DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-685/S-066 **PRIOR APPROVAL SUPPLEMENT**

Merck & Co., Inc.
Attention: Karen Henry
Associate Manager, Regulatory Affairs
UG2C-50, P.O. Box 1000
North Wales, PA 19454-1099

Dear Ms. Henry:

Please refer to your supplemental new drug application dated October 30, 2007, received October 30, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Crixivan™ (indinavir sulfate) capsules 100 mg, 200 mg, 333 mg and 400 mg.

This "Prior Approval" supplemental new drug application adds midazolam drug interaction information to the Warnings/Drug-Drug Interaction and Precaution sections of the package insert, adds the term "oral" to midazolam in the package and patient package insert and adds information about intravenous VERSED (midazolam) to the patient package insert.

We completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the submitted labeling text with minor editorial revisions (see table, text in **bold** below):

Submitted labeling text	Approved labeling text	Location in pi
If CRIXIVAN with or without ritonavir is co-administered with parenteral midazolam, it should be done **in an** [redacted] **setting** which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.	If CRIXIVAN with or without ritonavir is co-administered with parenteral midazolam, it should be done **in a setting** which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation	**WARNINGS** *Drug Interactions*
Dosage [redacted] for midazolam should be considered, especially if more than a single dose of midazolam is administered.	Dosage **reduction** for midazolam should be considered, especially if more than a single dose of midazolam is administered.	**WARNINGS** *Drug Interactions*
Coadministration should be done **in an** [redacted] **setting** which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation	Coadministration should be done **in a setting** which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation	**PRECAUTIONS** *Drug Interactions* **TABLE 9**

The final printed labeling (FPL) must be identical to the attached labeling (text for the package insert, text for the patient package insert) and include the minor editorial revision indicated.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81. If you have any questions, call Anne Marie Russell, Ph.D., Regulatory Project Manager, at (301) 796-2014.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director, Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Package Insert and Patient Package Insert

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jeffrey Murray

4/17/2008 04:10:27 PM